• Shelagh B Coutts, Eivind Berge, Bruce Cv Campbell, Keith W Muir, and Mark W Parsons.
• 1 Department of Clinical Neurosciences, Radiology, Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
• Int J Stroke. 2018 Dec 1; 13 (9): 885-892.

AbstractAlteplase has been the mainstay of thrombolytic treatment since the National Institutes of Neurological Disorders and Stroke trial was published in 1995. Over recent years, several trials have investigated alternative thrombolytic agents. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, has a longer half-life, allowing single intravenous bolus administration without infusion, is more fibrin specific, produces less systemic depletion of circulating fibrinogen, and is more resistant to plasminogen activator inhibitor compared to alteplase. Tenecteplase is established as the first-line intravenous thrombolytic drug for myocardial infarction, where it has been shown to achieve comparable reperfusion with reduced risk of systemic bleeding in comparison to alteplase. We review the literature on tenecteplase for the treatment of acute ischemic stroke, with a focus on the major completed and ongoing trials. Overall, tenecteplase shows promise for treatment of acute ischemic stroke, both in populations currently eligible for alteplase and also in groups not currently treated with thrombolysis.

23 keywords...

hide…